Trials / Unknown
UnknownNCT04229186
Pilot Study About Extra Virgin Olive Oil "Coratina" in Mild Cognitive Impairment and Alzheimer's Disease Patients
Pilot Study About Extra Virgin Oil "Coratina" (Evoo-c) in Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD) Patients (EVOO-c in MCI/AD)
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- University of Bari Aldo Moro · Academic / Other
- Sex
- All
- Age
- 50 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Alzheimer's Disease is a neurodegenerative disease age related caused by neurofibrillary tangles misfolding and Beta-amyloid protein accumulation. In the last decade several findings showed the role of biophenols present in diary intake such as extra virgin olive oil as potential antagonist of neurodegeneration. Two population studies (The Seven Countries Study and Three-City-Study) and four clinical trials (PREDIMED, PREDIMED - NAVARRA, ACTRIN and ISRCTN) have already suggested that mediterranean diet or other diets supplemented with extra virgin olive oil could improve cerebral performance.
Detailed description
24 MCI or Alzheimer's Disease patients will be recruited and randomised; 12 of them will receive extra virgin olive oil "coratina" (EVOO-C); 12 of them will receive biophenol low dose olive oil (ROO). Each patient will consume a total amount of 10 mg olive oil in a year (12 months). Clinical assessement will be based on: * neurological examination (T0, T6, T12); * cardiological examination (T0, T12): a supra-aortic vessels and brachial artery ecocolordoppler will be performed; * ophthalmological evaluation (T0, T12): a optic coherence tomography will be performed; * neuropsychological assessment (T0, T12); * nutritional assessement(T0, T3, T6, T9, T12). Each subject will perform: * brain MRI (T0, T12); * Beta Amyloid Positron Emission Tomography (T0, T12) A lumbar puncture will be ruled as well (T0) and markers of neurodegeneration (Beta-amyloid 1 - 42, total tau protein, fosfo-tau, Brain Derived Neurotrophic Factor (BDNF), Neurofilament (NFL) will be quantified); Renal, hepatic and nutritional status will be assessed 3 times in 12 months (T0, T6, T12).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | EVOO-C | Each patient will consume 10 mg total daily amount EVOO-C |
| DIETARY_SUPPLEMENT | ROO | Each patient will consume 10 mg total daily amount ROO |
Timeline
- Start date
- 2020-01-01
- Primary completion
- 2021-01-01
- Completion
- 2022-01-01
- First posted
- 2020-01-18
- Last updated
- 2020-01-18
Source: ClinicalTrials.gov record NCT04229186. Inclusion in this directory is not an endorsement.